SAFETY AND EFFICACY OF VINORELBINE PLUS LOW-DOSE METRONOMIC CYCLOPHOSPHAMIDE IN PATIENTS WITH METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH ANTHRACYCLINES AND TAXANES

被引：1
|
作者：
Kudo, S. [1 ]
Makino, T. [1 ]
Hasunuma, A. [1 ]
Ahiko, Y. [1 ]
机构：
[1] Yamagata Prefectural Cent Hosp, Yamagata, Japan
来源：
ANNALS OF ONCOLOGY | 2014年 / 25卷
关键词：
D O I：
10.1093/annonc/mdu329.55
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
406P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Safety and efficacy of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast
    Fedele, P.
    Orlando, L.
    Schiavone, P.
    Rizzo, P.
    Calvani, N.
    D'Amico, M.
    Marino, A.
    Sponziello, F.
    Cinieri, A. Nacci e S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [22] Biweekly vinorelbine and tegafur/uracil in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: GEICAM 2000–02 phase II study
    Antonio Antón
    Agustí Barnadas
    Jesús Florián
    Nuria Ribelles
    María Lomas
    Juan Lao
    Ana González-Quintás
    Mireia Margelí
    Ana Belén Paules
    Javier Gayo
    Manuel Ramos
    Clinical and Translational Oncology, 2011, 13
  • [23] Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes
    Alison Jones
    Mary O’Brien
    Harald Sommer
    Elzbieta Nowara
    Anja Welt
    Tadeusz Pienkowski
    Janusz Rolski
    My-Linh Pham
    Kevin Perraud
    Véronique Trillet-Lenoir
    Cancer Chemotherapy and Pharmacology, 2010, 65 : 755 - 763
  • [24] Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes
    Jones, Alison
    O'Brien, Mary
    Sommer, Harald
    Nowara, Elzbieta
    Welt, Anja
    Pienkowski, Tadeusz
    Rolski, Janusz
    Pham, My-Linh
    Perraud, Kevin
    Trillet-Lenoir, Veronique
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 65 (04) : 755 - 763
  • [25] Explorative Analysis of Low-Dose Metronomic Chemotherapy with Cyclophosphamide and Methotrexate in a Cohort of Metastatic Breast Cancer Patients
    Krajnak, Slavomir
    Battista, Marco
    Brenner, Walburgis
    Almstedt, Katrin
    Elger, Tania
    Heimes, Anne-Sophie
    Hasenburg, Annette
    Schmidt, Marcus
    BREAST CARE, 2018, 13 (04) : 272 - 276
  • [26] A phase II study of metronomic oral chemotherapy for metastatic breast cancer patients: Safety and efficacy results of vinorelbine, cyclophosphamide plus capecitabine (VEX) combination
    Montagna, E.
    Lai, A.
    Palazzo, A.
    Bagnardi, V.
    Cancello, G.
    Iorfida, M.
    Esposito, A.
    Sangalli, C.
    Munzone, E.
    Goldhirsch, A.
    Colleoni, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S291 - S292
  • [27] Gemcitabine in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Evaluation of response toxicity
    Lerzo, GL
    Temperley, G
    Rosales, C
    Campos, C
    Lezcano, A
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S74 - S74
  • [28] Low-dose metronomic oral cyclophosphamide plus prednisone for metastatic castration resistant prostate cancer (mCRPC) patients
    Martinez Lago, N.
    Anido, U.
    Vieito, M.
    Varela-Ponte, R.
    Carmona, M.
    Rodriguez, C.
    Cortegoso, A.
    Candamio, S.
    Lopez-Lopez, R.
    Leon, L.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S705 - S706
  • [29] Second-Line Combination Chemotherapy with Vinorelbine and Capecitabine in Patients with Advanced Breast Cancer Previously Treated with Anthracyclines and/or Taxanes
    Mao, Weidong
    Guan, Xunxing
    Tucker, Steven
    Li, Fengyan
    He, Zhenyu
    Wang, Junjie
    Guo, Jun
    Wu, Shangang
    CHEMOTHERAPY, 2011, 57 (01) : 71 - 76
  • [30] Efficacy and safety of eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with anthracycline/taxanes
    Chen, Lan
    Yan, Xi
    Luo, Ting
    Tian, Tinglun
    He, Ping
    Zhong, Xiaorong
    CANCER MEDICINE, 2024, 13 (10):
12345